CanSino Biologics Inc. (688185.SH): DTcP-Hib-MCV4 combination vaccine clinical trial application approved.

24/02/2025

GMT Eight

CanSino Biologics Inc. (688185.SH) announced that it recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the absorbed cell-free bivalent influenza diphtheria-ACYW135 group meningococcal (conjugate) combined vaccine (referred to as "DTcP-Hib-MCV4 combined vaccine").

Hygon Information Technology (688041.SH) achieved a net profit of 1.929 billion yuan in 2024, representing a year-on-year increase of 52.73%.

SSY GROUP (02005): Pibedil has been approved by the National Medical Products Administration (NMPA) for registration as an active pharmaceutical ingredient for use in marketed formulations.

Contact: contact@gmteight.com

CanSino Biologics Inc. (688185.SH): DTcP-Hib-MCV4 combination vaccine clinical trial application approved.

RECOMMEND

Hanyu Group Joint-Stock (300403.SZ): Net profit for the year 2024 was 234 million yuan, a decrease of 4.12% year-on-year.

China Securities Co., Ltd. (06066): China Securities Co., Ltd. International provided guarantees for the issuance of USD 0.7 billion in notes by CSCIF Hong Kong Limited.

Several senior executives and supervisors of Eaglerise Electric & Electronic (002922.SZ) plan to collectively reduce their holdings by no more than 482,300 shares.